What is the full generic name of the nintedanib drug product?

The full name of Nintedanib (Nintedanib) is "nintedanib ethanesulfonate soft capsule". It is a multi-target tyrosine kinase inhibitor commonly used to treat a variety of fibrosis-related diseases, especially idiopathic pulmonary fibrosis (IPF) and other types of interstitial lung diseases (ILDs). The mechanism of action of nintedanib involves the inhibition of multiple fibrosis pathways, which can effectively slow down the process of fibrosis and improve patients' lung function. The drug has been approved by drug regulatory authorities in several countries to treat certain types of lung diseases, particularly those chronic conditions that lead to pulmonary fibrosis.

As an important drug for the treatment of idiopathic pulmonary fibrosis and other interstitial lung diseases, nintedanib inhibits the proliferation and migration of fibroblasts by targeting multiple pathogenic signaling pathways (such as platelet-derived growth factor receptor, fibroblast growth factor receptor, vascular endothelial growth factor receptor, etc.), thereby slowing down the fibrosis of lung tissue. This mechanism allows nintedanib to exhibit unique efficacy in a variety of fibrosis-related diseases.

In addition to idiopathic pulmonary fibrosis, nintedanib is also indicated for the treatment of systemic sclerosis-related interstitial lung disease (SSc-ILD) and other types of progressive pulmonary fibrosis. Its effect in improving patients' lung function and delaying disease progression has been verified in multiple clinical studies.

In general, nintedanib (Nintedanib), as a therapeutic drug with a wide range of indications, has been approved by countries around the world for the treatment of pulmonary fibrosis-related diseases and has achieved significant clinical results. By reducing the progression of pulmonary fibrosis, it results in longer survival and better quality of life for patients with these diseases.

Reference materials:https://en.wikipedia.org/wiki/Nintedanib